The company has signed an expanded research collaboration agreement with the Department of Public Health and Caring Sciences, Molecular Geriatrics, Uppsala University, concerning antibody-based diagnostic imaging of the brain in Alzheimer patients.
The collaboration concerns further development of technologies for antibody-based diagnostic imaging (PET – Positron Emission Tomography). Antibody-based imaging is a totally new principle for imaging of the brain. The antibody-based PET ligands can provide additional information compared to currently available PET ligands.
The long-term goal
The long-term goal of the research collaboration is to be able to offer health care professionals and patients an improved method for the diagnosis of Alzheimer’s disease, and also to improve the possibilities to evaluate the effect of pharmacological treatment.
BioArctic will provide financial support for a three-year research position, with potential extension.
“We look forward to continuing the research collaboration with Uppsala University regarding new PET ligands based on our antibodies. This initiative is of importance to the entire field of Alzheimer research. We hope that the results will contribute to improved diagnosis of Alzheimer patients in the future and thus to a more effective treatment,” says Gunilla Osswald, CEO of BioArctic.
